Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06459869
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-06-11
Brief Title:
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Sponsor:
Akamis Bio
Organization:
Akamis Bio
Study Overview
Official Title:
A Multicentre Open-label Non-randomized Phase 1b Trial of NG-350A a Tumour-selective Anti-CD40-expressing Adenoviral Vector in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer FORTRESS
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FORTRESS
Brief Summary:
The FORTRESS trial NG-350A-03 is an open-label single-arm and multicentre trial of NG-350A in combination with chemoradiotherapy CRT in adult patients with locally advanced rectal cancer LARC and at least one risk factor for local or distant recurrence
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None